This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA leverages cross-functional expertise to deliver best-in-class services to clients in the Life Sciences sector including strategic consulting, IP litigation, antitrust, and transfer pricing. Life sciences companies have high-stakes transfer pricing issues due to their high-value IP and the risks embedded within the value chain. CRA’s transfer pricing economists have assisted numerous pre-clinical biotech companies with their initial international expansion and IP planning; and commercial-phase companies design and document intercompany pricing policies relating to their physical goods supply chains. CRA experts have provided expert witness reports in GlaxoSmithKline vs. Commissioner and in state transfer pricing disputes.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comVice President, Practice Leader of Transfer Pricing
Oakland
+1-510-595-3098 rcurd@crai.comhe/him/his
Vice President, Transfer Pricing Leader for Canada
Toronto
+1-416-323-5563 dkemp@crai.comRebel Curd, Robin Hart, and two tax lawyers were interviewed for an October 14, 2022 Law360 Tax Authority article about an unspecified transfer pricing method...
The first US transfer pricing court decision of 2022 was published on Thursday, August 18, 2022, specifically Medtronic, Inc. and Consolidated Subsidiaries v....
